When captopril was injected intravenously in urethane anesthetized rats, a hypotensive effect accompanied by bradycardia was obtained, while an intravenous (i. v.) injection of prostaglandin I2 (PGI2), which induced hypotension of the same magnitude as the hypotensive effect obtained with captopril, caused a marked tachycardia. Simultaneously, sympathetic nerve activity recorded from abdominal sympathetic nerves was unchanged following injection of captopril, while it was significantly increased during hypotension induced by PGI2. The bradycardia, but not the hypotensive effects induced by captopril was abolished by i. v. pretreatment with atropine. Intracisternal injection of a small dose of captopril inhibited reflex tachycardia during hypotension induced by PGI2 and prolonged the hypotensive effect, while intravenous administration of this dose did not inhibit the reflex tachycardia induced by PGI2. In spontaneously hypertensive rats (SHR), the hypotensive effect of captopril was increased partly, however, the accompanying bradycardia was significantly reduced. These findings suggest that captopril inhibits the baroreflex and centrally activates the cardiac vagal nerve. Moreover in SHR, the effect of captopril on cardiac vagal activity was disturbed.
Jpn. Heart J. July 1986 hypertension, especially since the development of captopril which is a potent and specific orally active converting enzyme inhibitor.2) Captopril prevents the production of circulating angiotensin II (A II)3) and also the inactivation of bradykinin by inhibition of angiotensin converting enzyme (ACE; Kininase II).4),5) However, recently, evidence has accumulated that the antihypertensive effect of captopril cannot be explained solely by these actions.6)-9)
In the complex mechanisms of action of captopril, the effect of captopril on the baroreflex mechanism might contribute in part to the reduction of blood pressure. This hypothesis is based on reports that captopril does not elicit reflex tachycardia in humans10)-12) and animals,13) while hypotension induced by peripherally acting antihypertensive drugs usually increases heart rate via the baroreflex. The purpose of the present study was to determine whether captopril could inhibit the baroreceptor reflex system during hypotension and thus contribute to the hypotensive effect of captopril in normotensive and spontaneously hypertensive rats. (Table  II) . Sympathetic nerve activity during hypotension induced by captopril Following intravenous injection of captopril, sympathetic nerve activity was not altered, while injection of PGI2 elicited by increases in sympathetic nerve activity during hypotension was accompanied by tachycardia. These differences between the 2 groups were significant for 2min after administra- tion of drugs (Table III) . These findings suggest that captopril may inhibit the baroreflex.
METHODS
Intracisternal treatment of captopril reduced reflex tachycardia induced by i. v. injections of PGI2
To determine whether captopril acts centrally to inhibit the baroreflex, tachycardia induced by PGI2 was recorded after intracisternal treatment with captopril. As a control, saline was injected intracisternally in other rats. Reflex tachycardia during hypotension induced by i. v. injection of PGI2 was significantly inhibited in captopril treated rats, while tachycardia was not affected in the saline treated rats. To eliminate the possibility that captopril leaking from the brain might act peripherally to inhibit tachycardia, the same dose of captopril was administrated intravenously.
However, it did not reduce the reflex tachycardia induced by PGI2 (Table IV) . Moreover, to determine if this inhibition of reflex tachycardia contributes to the hypotensive effect of captopril, the hypotension induced by i. v. injection of PGI2 was compared in 2 groups with or without intracisternal administration of captopril. WKY than in the controls (Fig.3) . These findings suggest that cardiac vagal activity in Kyoto Wistar rats may be changed and it may be most obvious in SHR. DISCUSSION I. V. injection of captopril lowered the blood pressure in urethane anesthetized normotensive and spontaneously hypertensive rats. In normotensive rats, the hypotensive effect of captopril was accompanied by bradycardia and sympathetic nerve activity was not altered following i. v. injection of captopril. The bradycardia induced by captopril disappeared after pretreatment with Jpn. Heart J. July 1986 atropine. These results indicate that i. v. captopril not only inhibits the baroreflex, but also activates the cardiac vagal nerve in normotensive rats. However, the activation of the vagal nerve does not contribute to the hypotensive effect of captopril, because atropine did not affect the depressor responses induced by captopril. Since intracisternal injection of captopril (2mg/kg) elicited an enhanced bradycardiac response, the activation of the cardiac vagal nerve might be central. The activation of the vagal component has also been seen clinically after treatment with captopril.15) The blunted baroreflex which was seen in the cardiovascular responses to captopril was confirmed by the lack of an increase in sympathetic nerve activity during the hypotension induced by captopril, while PGI2 increased sympathetic nerve activity following the hypotension. There are three possible sites where captopril could act to inhibit the baroreflex. First, at baro-receptors located in the aortic arch, carotid sinus and a few others, second, centrally and third at the efferent nerve endings. Because reflex increases of efferent sympathetic nerve activity were depressed after treatment with captopril in the present study, and it is reported that captopril did not reduce the release of norepinephrine in WKY and SHR,16) the third possibility is not likely. Central administration of captopril inhibited reflex tachycardia which was elicited following hypotension induced by i. v. injection of PGI2. This finding suggests that captopril inhibits the baroreflex centrally. Bradycardia is due to the activation of the cardiac vagal nerve, since atropine treatment abolished bradycardia. However, after atropine injection, reflex tachycardia did not reappear. The lack of tachycardia showed the lack of an increase in cardiac sympathetic nerve activity. In the present study, because i. v. injection of the same dose as the intracisternal injection of captopril did not reduce the reflex tachycardia induced by PGI2, the possibility that captopril could directly affect baro-receptors is small. Recently, it has been reported17) that captopril can penetrate the brain blood barrier. But even if it cannot,18) the area postrema is not covered by the barrier near the brain stem. Therefore, captopril administered i. v. could easily reach the brain stem where the baroreflex center is located.19) In our study, we could not determine whether the central inhibition of the baroreflex by captopril resulted from a reduction in central angiotensin II. However, our results confirmed that this inhibition of the baroreflex contributed in part to the hypotensive effect of captopril, since central administration of captopril prolonged the hypotension induced by i. v. injection of PGI2.
There have been many theories as to the hypotensive mechanisms of this drug, including the reduction of plasma angiotensin II,3) the activation of bradykinin,4),5) the inhibition of brain20),21) or vascular angiotensin9),22) and the activation of the prostaglandin system.23) However, since no one of these by itself can explain fully the hypotensive effect of captopril, it is probable that a number of these factors act in concert to reduce the blood pressure. The inhibitory effect of captopril on the baroreflex is possibly one of multiple factors. The lack of reflex tachycardia has also been reported by others in humans10)-12) and animals.14) This modulation of the baroreflex by captopril was reported as a potentiation of the baroreflex, since the bradycardia response during pressor responses to i. v. injection of phenylephrine was augmented in captopril treated rats.24) The present study did not examine the baroreflex responses during pressor responses, however, it is possible that captopril blunted the baroreflex in the lower portion of the stimulus-response curve of the baroreflex. This difference in baroreflex response following treatment with captopril was observed in essential hypertension after treatment with captopril.25) Present experiments were undertaken in anesthetized rats. However, the hypotensive effect of captopril is not accompanied by reflex tachycardia in awake rats as well.26) Therefore, the cardiovascular responses elicited by captopril are not specific to anesthetized rats.
In addition to its effect on normotensive rats, captopril also reduces the blood pressure in urethane anesthetized SHR. The hypotensive effect of captopril was significantly more enhanced in the early phase in SHR than in WKY. This enhancement of the hypotensive effect of captopril occurred only within the first minute, but the present study did not clarify the mechanism of enhancement.
Heart rate responses to i. v. injection of captopril in SHR were significantly different from those of normotensive rats. The differences in cardiovascular responses to captopril between WKY and SHR might have been due to the effect of anesthesia on plasma renin activity (PRA), but this was not measured in the present study. However, this is unlikely, since the enhanced hypotensive effect in SHR was only transient in the early phase. If activated PRA in SHR induced enhanced hypotension, the hypotensive effects should have continued for as long as captopril was effective. The lack of bradycardiac responses in SHR could not have been due to the reduction of angiotensin II, because angiotensin II itself diminishes or does not alter baroreflex sensitivity.27) These findings suggest that the baro-receptor system in SHR is deranged.
However, WKY which is the mother strain of SHR also demonstrated small bradycardia responses to captopril. This indicates that cardiac vagal activity in these strains is different from that in normotensive rats.
